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Background
This study evaluated the potential global market size and
value of a hypothetical preventive HIV-1 vaccine that
takes into account clade specificity, partial prevention of
infection, impact on transmission, delay to treatment, and
healthcare system differences regarding HIV-1 screening
and its impact on potential market size.
Methods
The potential market size and value of a hypothetical HIV-
1 vaccine effective against HIV-1 clades A, B and C was
assessed across five different potential product profiles
using an Excel-based spreadsheet model. Vaccine efficacy
(prevention of acquisition and/or decrease in virus load),
disease burden, clade distribution, vaccine price, market
segment, vaccine delivery infrastructure, and HIV screen-
ing capabilities were taken into account. It was assumed
that high disease burden countries (HDBC) where HIV
prevalence rates are >1% would routinely vaccinate ado-
lescents, whereas low disease burden countries (LDBC)
with HIV prevalence rates < 1% would routinely vaccinate
high-risk groups only. Routine vaccination and one-time
catch-up campaigns were assessed.
Results
Potential demand and market value was seen across all
product profiles and increased with disease impact (e.g.,
decrease on HIV-1 transmission and delay in time to treat-
ment) and increased efficacy (0% – 60%). The overall
potential demand during the routine and catch-up cam-
paign vaccination period was estimated to be 130–270
million peak annual doses in HDBC and 20–60 million
peak annual doses in LDBC. The potential value was
related to the product profile but was greater than $200
million annually, even for a vaccine expected to modestly
decrease transmission and delay treatment by 1–2 years.
Conclusion
This study evaluated in detail the value of a multi-clade
HIV-1 vaccine taking into account vaccine, disease, and
healthcare complexities. The findings of this study pro-
vide donors and suppliers new data to consider in their
continuing efforts to develop an HIV-1 vaccine that
addresses clades relevant to worldwide disease burden.
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